Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Clinical trial NCT05091372 · RECRUITING
Trial details
- NCT number
- NCT05091372
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2027-12-31
- Enrollment
- 94
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.